Bevacizumab in The Treatment of Kras Wild Type Metastatic Colorectal Cancer: An Economic Analysis Based on The Calgb 80405 Trial

Silva, C; Monteiro, I.; Tournier, C.

doi:10.1016/j.jval.2016.09.2157

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…European cost data could be more comparable due to the similarities in health care systems and size of the economies. For instance, Portuguese cost study calculated the cost EUR 2,057 per month with bevacizumab in the first line treatment [25] which correspond to our study -the average cost of bevacizumab was about EUR 2,500. In the Finish cost study of CRC the total direct medical costs were approximately EUR 2,380 per month [9].…”

Section: Costs Of Mcrc Treatmentsupporting

confidence: 79%

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

Sehnalová¹

2020

FARMACIA

View full text Add to dashboard Cite

Targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab are reimbursed in the Czech Republic in combination with chemotherapy or alone in metastatic colorectal cancer (mCRC). However, the high cost is a potentially limiting factor. The real-world costs and effectiveness of first line bevacizumab followed by cetuximab or panitumumab (EGFRi) were retrospectively assessed from the perspective of healthcare payer. Total 71 WT KRAS patients (56% men; median age 60.5 years) were evaluated between April 2007 and May 2017. During our follow-up period (30 months on average) 55% patients died. The mean cost to PD was EUR 32,107 and EUR 24,510 in bevacizumab and EGFRi treatment respectively with median PFS 9.7 and 5.0 months. The median overall survival was 27.2 months and the mean cost from sequential therapy initiation to death was EUR 63,682. The targeted therapy made up 77%, 86% and 76% of the costs in the first line, second line and from the initiation of sequential therapy to death respectively. RezumatAnticorpii monoclonali bevacizumab, cetuximab și panitumumab sunt rambursați în Republica Cehă atât în monoterapie sau în combinație chimioterapice. Cu toate acestea, costul ridicat este un factor potențial limitativ. Costurile reale și eficacitatea bevacizumab, cetuximab și panitumumab (EGFRi) au fost evaluate în mod retrospectiv din perspectiva plătitorului de servicii medicale. 71 de pacienți KRAS KTT (56% bărbați; vârsta medie 60,5 ani) au fost evaluați în perioada aprilie 2007mai 2017. În perioada de urmărire (în medie 30 de luni), 55% dintre pacienți au murit. Costul mediu pentru progresia bolii a fost de 32.107 EUR și de 24.510 EUR în tratamentul cu bevacizumab și, respectiv, cu EGFRi. Supraviețuirea mediană totală a fost de 27,2 luni, iar costul mediu de la inițierea terapiei secvențiale până la deces a fost de 63.682 EUR. Terapia vizată a constituit 77%, 86% și 76% din costurile aferente primei linii, celei de-a doua și respectiv de la inițierea terapiei secvențiale până la deces.

show abstract

Section: Costs Of Mcrc Treatmentsupporting

confidence: 79%

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

Sehnalová¹

2020

FARMACIA

View full text Add to dashboard Cite

show abstract

Bevacizumab in The Treatment of Kras Wild Type Metastatic Colorectal Cancer: An Economic Analysis Based on The Calgb 80405 Trial

Cited by 1 publication

References 0 publications

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS

Contact Info

Product

Resources

About